Morgan Stanley Double Upgrade Blows BIIB Out of the Water

The analysts also lifted its price target to $357

Digital Content Manager
Jul 27, 2020 at 10:36 AM
facebook twitter linkedin

Pharmaceutical name Biogen Inc (NASDAQ:BIIB) is soaring today, up 4.2% to trade at $283.89, on a double upgrade from Morgan Stanley. The analyst lifted its rating to "overweight" from "underweight" and hiked its price target to $357 from $263, praising the firm's Alzheimer's candidate aducanumab. 

The majority of analysts, meanwhile, were hesitant. Just seven called BIIB a "strong buy" coming into today, while 13 said "hold" and five said "sell" or worse. Plus, the consensus 12-month price target of $300.54 is a slim 5.8% premium to current levels. 

Elsewhere, sentiment is optimistic. BIIB sports a 50-day call/put volume ratio of 1.62 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 80% readings from the past year. Plus, in the past reporting period, short interest fell 29.9% and now makes up just a slim 2% of the security's available float. 

Though Biogen stock hasn't been performing as well as some of its sector peers, the equity is still up 19.3% in the last 12-months, with the $270 level providing some support since the stock gaped above the area back in October 2019. And while BIIB slipped below support at its 20-day moving average late last week, it is on track to re-champion this trendline during today's trading. 



If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners